Bristol-Myers Squibb Taxol
Executive Summary
Supplemental NDA for paclitaxel as combination adjuvant chemotherapy for women with node-positive breast cancer is submitted. The sNDA is based on a 3,000-woman study that compared paclitaxel in combination with doxorubicin and cyclophosphamide to the two drugs alone